Outlook Therapeutics (OTLK) Receivables - Other (2015 - 2016)
Outlook Therapeutics (OTLK) posted quarterly Receivables - Other of $43350.0 for Q2 2016, little changed quarter-over-quarter from $43187.0 in Q1 2016.
Outlook Therapeutics (OTLK) Receivables - Other (2015 - 2016) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Receivables - Other for 2 consecutive years, with $43350.0 the latest figure, recorded in Q2 2016.
- In Q2 2016, Receivables - Other changed N/A year-over-year to $43350.0; the TTM figure through Jun 2016 stood at $43350.0 (changed N/A YoY), while the FY2015 annual figure was $117506.0, changed N/A from the prior year.
- Receivables - Other steadied at $43350.0 in Q2 2016 per OTLK's latest filing, from $43187.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $117506.0 in Q3 2015 and bottomed at $43187.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 43,350.00 |
| Jun 30, 2016 | 43,350.00 |
| Mar 31, 2016 | 43,187.00 |
| Mar 31, 2016 | 43,187.00 |
| Sep 30, 2015 | 117,506.00 |
| Sep 30, 2015 | 117,506.00 |